Drug Trial Radar · NCT06361108
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
May 16, 2024
Primary completion
Dec 20, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase I, randomized, double-blind and placebo controlled study is to evaluate the safety, tolerability, and PK, and to preliminarily assess the efficacy of topically administered YJ001 in a multiple-ascending dose (MAD) fashion in the patients with DPNP. The study will be conducted at a single study center. In this study, 2 cohorts (N=24, 12 subjects for each cohort), each cohort will consist of 10 active and 2 placebo, with approximately equal numbers of male and female subjects. Each subject will be administered a single dose of YJ001 as multiple sprays topically on both feet and below the ankle in the morning on Day 1 and Day 2, and will be administered as twice daily doses once in the morning and the other in the evening (with an interval of 11 to 13 h) from Day 3 through Day 11.
Conditions
- Diabetic Peripheral Neuropathic Pain
Interventions
YJ001 for Spray UseDrug
Granules for spray use; Preparation of Dosing Solution: Reconstitute with sterile water (50ml)
Placebo of YJ001 for Spray UseDrug
Inactive Ingredient: Sterile water; Preparation of Dosing Solution: 50ml Sterile water
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Assessments - AEsTime frame: through study completion, an average of 1year
- Safety Assessments -Number of Participants With Abnormal Laboratory ValuesTime frame: through study completion, an average of 1year
- Safety Assessments - Skin ReactionTime frame: through study completion, an average of 1year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trials of Texas,LLC
Fredericksburg, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.